Sara Blumenstein, Ph.D.

Pharma & Biotechnology Regulatory Section Manager

Dr. Blumenstein received her B.Sc. with distinction from Ben Gurion University, Beer-Sheva, MSc and Ph.D from the Weizmann Institute of Science, Rehovot in the field of biochemistry, and was a Post-Doctoral fellow in the field of human DNA repair at the Weizmann Institute of Science.

Sara has over 14 years experience in Biotechnology and cell therapy fields (ProChon Biotech and KSC labs). Dr. Blumenstein has managed the R&D and QC groups at ProChon Biotech and was responsible for improving a cartilage repair product marketed in Israel which was also undergoing clinical study under IND, developed QC release assays for this product, headed  technology transfer projects, protein formulation and protein scaffold production, characterized mesenchymal stem cells for cartilage repair therapy as part of the Bereshit consortium (founded by the Chief Scientist in the Israeli Office of Industry, Trade & Labor). Sara was also a project manager in KSC labs and designed an immunotherapy product based on mesenchymal stem cells.

In her position at Gsap, Sara is leading improvement processes of quality systems in biotechnology and cell therapy companies, preparing and submitting regulatory documents to FDA and MOH for Pharma and biotechnology companies.

At Gsap Sara led Projects for the following companies: department of bone marrow transplantation, Hadassah medical center, Midgam (tissue bank), Compugen, Ophtimed, CureTech, Phibro Abic, Suri, Orasis, Omnix, TPCera, N2B and TouchBrain.